European Journal of Cancer
Volume 45, Issue 14 , Pages 2569-2573 , September 2009

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?

  • Rhiannon C. Macefield

      Affiliations

    • Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
    • Corresponding Author InformationCorresponding author: Tel.: + 44 (0)117 928 7367; fax: + 44 (0)117 331 3914.
    • ,
  • J. Athene Lane

      Affiliations

    • Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
    • ,
  • Chris Metcalfe

      Affiliations

    • Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
    • ,
  • Liz Down

      Affiliations

    • Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
    • ,
  • David E. Neal

      Affiliations

    • University Department of Oncology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    • ,
  • Freddie C. Hamdy

      Affiliations

    • Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
    • ,
  • Jenny L. Donovan

      Affiliations

    • Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK

Received 4 February 2009 ,Revised 9 March 2009 ,Accepted 17 March 2009.

References 

  1. de Koning HJ, Auvinen A, Sanchez AB, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer. 2002;97(2):237–244
  2. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98(8):529–534
  3. Graham J, Baker M, Macbeth F, Titshall V. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ. 2008;336:610–612
  4. Wilt TJ. Commentary: controversies in NICE guidance on prostate cancer. BMJ. 2008;336:612–614
  5. Cancer statistics registrations. Registrations of cancer diagnosed in 2004, England. London: Office for National Statistics; 2006.
  6. Bratt O. Hereditary prostate cancer. BJU Int. 2000;85:588–598
  7. Fitzpatrick JM, Blackledge G, Newling D. PSA – promotor of stress and anxiety or providentially-sent antigen?. Eur Urol Suppl. 2002;1:10–14
  8. Nam RK, Toi A, Klotz LH, et al. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Can J Urol. 2006;13(Suppl. 2):2–10
  9. Brindle LA, Oliver SE, Dedman D, et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int. 2006;98:777–782May 26
  10. Essink-Bot M-L, de Koning HJ, Nijs HGT, Kirkels WJ, van der Maas PJ, Schröder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst. 1998;90:925–931
  11. Hensley ML, Robson ME, Kauff ND, et al. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol. 2003;89(3):440–446
  12. Donovan JL, Hamdy FC, Neal DE, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1–49
  13. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370
  14. Avery KNL, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol. 2008;53:1186–1193
  15. Avery KNL, Metcalfe C, Blazeby JM, et al. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. BJU Int. 2008;102(11):1629–1633
  16. Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) – results from a prospective, population-based, randomised study. Eur J Cancer. 2007;43:2109–2116
  17. Roth AJ, Rosenfield B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer. Cancer. 2003;97(11):2910–2918
  18. Metcalfe C, Evan S, Ibrahim F, et al. Pathways to diagnosis for black men and white men found to have prostate cancer: the PROCESS cohort study. Br J Cancer. 2008;99(7):1040–1045
  19. Schulman CC, Kirby R, Fitzpatrick JA. Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol. 2003;44(3):294–302
  20. American Cancer Society [homepage on the Internet]. American Cancer Society, Inc.; [cited 2008 June 26]. Available from: http://www.cancer.org/docroot/home/index.asp.
  21. NHS Cancer Screening Programmes [homepage on the Internet]. NHS Cancer Screening Programmes; [cited 2008 June 26]. Available from: http://www.cancerscreening.nhs.uk/.
  22. Cancerbackup [homepage on the Internet]. Cancerbackup; c2003 [cited 2008 June 26]. Available from: http://www.cancerbackup.org.uk/.
  23. Ziebland S, Chapple A, Dumelow C, Evans J, Prinjha S, Rozmovits L. How the internet affects patients’ experience of cancer: a qualitative study. BMJ. 2004;328:564
  24. Robb KA, Miles A, Campbell J, Evans P, Wardle J. Can cancer risk information raise awareness without increasing anxiety? A randomized trial. Prev Med. 2006;43:187–190
  25. Edwards AGK, Evans R, Dundon J, Haigh S, Hood K, Elwyn GJ. Personalised risk communication for informed decision making about taking screening tests. Cochrane Database Syst Rev. 2006;(4):

PII: S0959-8049(09)00215-9

doi: 10.1016/j.ejca.2009.03.016

European Journal of Cancer
Volume 45, Issue 14 , Pages 2569-2573 , September 2009

Article Tools